Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes
Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, Melero I, Schalper KA, Herbst RS. Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes. Clinical Cancer Research 2019, 25: 4592-4602. PMID: 30824587, PMCID: PMC6679805, DOI: 10.1158/1078-0432.ccr-18-1538.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNon-small cell lung cancerImmune checkpoint inhibitorsCell lung cancerPD-L1Lung cancerNonsquamous non-small cell lung cancerOngoing translational workPD-1 axisFirst-line therapyPD-L1 expressionProportion of patientsTumor mutational burdenAdvanced diseaseOverall survivalTumor inflammationMutational burdenPatientsNovel markerChemotherapyTherapyIndicative biomarkersCancerTranslational workBiomarkersSurvivalComparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade
Lu S, Stein JE, Rimm DL, Wang DW, Bell JM, Johnson DB, Sosman JA, Schalper KA, Anders RA, Wang H, Hoyt C, Pardoll DM, Danilova L, Taube JM. Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade. JAMA Oncology 2019, 5: 1195-1204. PMID: 31318407, PMCID: PMC6646995, DOI: 10.1001/jamaoncol.2019.1549.Peer-Reviewed Original ResearchAnti-PD-1/PD-L1 therapyPD-L1 immunohistochemistryTumor mutational burdenPD-L1 therapyGene expression profilingMutational burdenAnti-PD-1/PD-L1 treatmentPD-1/PD-L1 checkpoint blockadeAnti-PD-1/PD-L1Tumor typesPD-L1 checkpoint blockadeDifferent solid tumor typesPD-L1 treatmentPretreatment tumor tissueImmunotherapy of cancerDrug Administration approvalSearch of PubMedMeta-Analyses (PRISMA) guidelinesSolid tumor typesNegative predictive valuePreferred Reporting ItemsAnnual meeting abstractsNegative likelihood ratioRelative diagnostic performanceCheckpoint blockade